Table III.
HLA/HNA antibody investigations in donors associated with TRALI cases between 1999–2019
| Investigations | All donors | Male | Female |
|---|---|---|---|
| Antibody screen | (n=238 donors) | (n=131 donors) | (n=107 donors) |
| HLA/HNA antibodies detected | 76 (31.9%) | 30 (12.6%) | 46 (19.3%) |
| HLA/HNA antibodies not detected | 158 (66.4%) | 98 (41.2%) | 61 (25.6%) |
| Not tested | 4 (1.7%) | 3 (1.3%) | 1 (0.4%) |
| Antibody specificity donors) | (n=76 | (n=30 donors) | (n=46 donors) |
| HNA only | 18 (23.7%) | 8 (10.5%) | 10 (13.2%) |
| HLA class I only | 22 (28.5%) | 13 (17.1%) | 9 (11.8%) |
| HLA class II only | 16 (21.1%) | 7 (9.2%) | 9 (11.8%) |
| Multiple types (HLA class I, II and/or HNA) | 20 (26.3%) | 2 (2.6%) | 18 (23.7%) |
| Donor outcomes | (n=238 donors) | (n=131 donors) | (n=107 donors) |
| Donor deferred | 117 (49.2%) | 52 (21.8%) | 65 (27.3%)a |
| Donor cleared | 121 (50.8%) | 79 (33.2%) | 42 (17.6%)a |
a
p-value <0.05 vs male donors.